RxDoctor Payments Data

Parul Jani, MD

Internal Medicine · Prince Frederick, MDNPI 1174527501

Payments from drug & device makers

$13,596in general payments, 2019–2025

Across 570 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$2K
  • AbbVie$1K
  • Novo Nordisk$987
  • GSK$929
  • Merck$710
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$13,36998%
  • Education$2272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,596 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$157,261
Medicare patients
313
Services billed
2,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$79,617
EliquisApixaban47$73,858
FarxigaDapagliflozin Propanediol29$41,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$29,361
JardianceEmpagliflozin17$22,766
TrintellixVortioxetine Hydrobromide17$20,866
XareltoRivaroxaban12$19,738
Repatha SureclickEvolocumab14$16,941
Rosuvastatin Calcium192$3,828
Varenicline Tartrate12$3,408
Metoprolol Succinate136$2,377
Albuterol Sulfate HfaAlbuterol Sulfate44$2,273
Atorvastatin Calcium197$2,266
Losartan Potassium123$2,186
Trazodone Hcl105$2,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$987$79,61737 claims
PfizerEliquis$645$73,85847 claims
AstraZenecaFarxiga$2,639$41,53929 claims
GSKTrelegy Ellipta$929$29,36117 claims
Boehringer IngelheimJardiance$578$22,76617 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$329$20,86617 claims
Johnson & JohnsonXarelto$34$19,73812 claims
AbbVieSynthroid$1,234$66218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Prince Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →